EyePoint (EYPT) Cash from Investing Activities (2010 - 2026)
EyePoint (EYPT) reported Cash from Investing Activities of $59.1 million for Q1 2026, up 49.41% on a YoY basis from $39.5 million in Q1 2025, and up 179.09% sequentially from -$74.7 million in Q4 2025.
EyePoint (EYPT) Cash from Investing Activities (2010 - 2026) Analysis & Trends
EyePoint (EYPT) has 17 years of Cash from Investing Activities data on file, last reported at $59.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 49.41% year-over-year to $59.1 million; the trailing twelve-month figure through Mar 2026 stood at $88.1 million (up 143.91% YoY), and the FY2025 full-year result was $68.6 million, up 131.26% from the prior year.
- Cash from Investing Activities climbed to $59.1 million in Q1 2026, from -$74.7 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $59.1 million in Q1 2026 to a low of -$160.4 million in Q2 2024.
- A 5-year average of -$6.6 million and a median of $13.5 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 112325.0% in 2023 and sank 1291.02% in 2024, its largest moves.
- Tracing EYPT's Cash from Investing Activities over 5 years: stood at $32.9 million in 2022, then sank by 243.23% to -$47.1 million in 2023, then plunged by 103.53% to -$96.0 million in 2024, then gained by 22.19% to -$74.7 million in 2025, then jumped by 179.09% to $59.1 million in 2026.
- Business Quant data shows EYPT's Cash from Investing Activities at $59.1 million in Q1 2026, -$74.7 million in Q4 2025, and $55.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | EyePoint | 1.07 Mn | -221.48 Mn | 168,000.00 | 59.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.05 Mn |
| Mar 31, 2026 | 59.05 Mn |
| Dec 31, 2025 | -74.67 Mn |
| Dec 31, 2025 | -74.67 Mn |
| Sep 30, 2025 | 55.39 Mn |
| Sep 30, 2025 | 55.39 Mn |
| Jun 30, 2025 | 48.34 Mn |
| Jun 30, 2025 | 48.34 Mn |
| Mar 31, 2025 | 39.53 Mn |
| Mar 31, 2025 | 39.53 Mn |
| Dec 31, 2024 | -95.96 Mn |
| Dec 31, 2024 | -95.96 Mn |
| Sep 30, 2024 | 16.20 Mn |
| Sep 30, 2024 | 16.20 Mn |
| Jun 30, 2024 | -160.40 Mn |
| Jun 30, 2024 | -160.40 Mn |
| Mar 31, 2024 | 20.81 Mn |
| Mar 31, 2024 | 20.81 Mn |
| Dec 31, 2023 | -47.15 Mn |
| Dec 31, 2023 | -47.15 Mn |